I live in a faded seaside town called St. Leonards-on-Sea, in Sussex, on the south coast of England. If you’ve not heard of it, you’re in good company. It’s not on anybody’s list of celebrated English beauty spots. Indeed, most of my riding is across flat coastal marsh or down-at-the-heel seafront promenades.
A year ago, as a travel photographer grounded by the pandemic, I started bringing a camera and tripod with me on my morning bicycle rides, shooting them as though they were magazine assignments.
It started out as just something to do — a challenge to try to see the familiar through fresh eyes. Soon it blossomed into a celebration of traveling at home.
“It may be good for you,” says Dariush Mozaffarian, dean of the Friedman School of Nutrition Science and Policy at Tufts University. “I think we can say with good certainty it’s not bad for you.” (Additives are another story.)
After the link appeared between coffee intake and a reduced risk of heart failure in the Framingham data, Kao confirmed the result by using the algorithm to correctly predict the relationship between coffee intake and heart failure in two other respected data sets. Kosorok describes the approach as “thoughtful” and says that it “seems like pretty good evidence.”
Should you drink coffee? If so, how much? These seem like questions that a society able to create vaccines for a new respiratory virus within a year should have no trouble answering. And yet the scientific literature on coffee illustrates a frustration that readers, not to mention plenty of researchers, have with nutrition studies: The conclusions are always changing, and they frequently contradict one another.
How Cade got access to the stories behind some of the biggest advancements in AI, and the dynamic playing out between leaders at companies like Google, Microsoft, and Facebook.
Cade Metz is a New York Times reporter covering artificial intelligence, driverless cars, robotics, virtual reality, and other emerging areas. Previously, he was a senior staff writer with Wired magazine and the U.S. editor of The Register, one of Britain’s leading science and technology news sites. His first book, “Genius Makers”, tells the stories of the pioneers behind AI.
Topics discussed: 0:00 Sneak peek, intro 3:25 Who is “Genius Makers” for and about? 7:18 *Spoiler alert!* Artificial General Intelligence (AGI) 11:01 How the story continues after the book ends 17:31 Overinflated claims in AGI 23:12 Deep Mind, OpenAI, and AGI 29:02 Outsider perspectives 34:35 Early adopters of ML 38:34 Who gets credit for what? 42:45 Dealing with bias 46:38 Aligning technology with nee
In the coming weeks, major airlines including United, JetBlue and Lufthansa plan to introduce a health passport app, called CommonPass, that aims to verify passengers’ virus test results — and soon, vaccinations. The app will then issue confirmation codes enabling passengers to board certain international flights. It is just the start of a push for digital Covid-19 credentials that could soon be embraced by employers, schools, summer camps and entertainment venues.
The advent of electronic vaccination credentials could have a profound effect on efforts to control the coronavirus and restore the economy. They could prompt more employers and college campuses to reopen. They may also give some consumers peace of mind, developers say, by creating an easy way for movie theaters, cruise ships and sports arenas to admit only those with documented coronavirus vaccinations.
The CommonPass, IBM and Clear apps, for instance, allow users to download their virus test results — and soon their vaccinations — to their smartphones. The apps can then check the medical data and generate unique confirmation codes that users can show at airports or other locations to confirm their health status.
But the health passes do not share specific details — like where and when a user was tested — with airlines or employers, developers said. The QR codes, they said, act merely as a kind of green light, clearing users for entry.
Even now, the approach to the 1,200-acre property is just as it must have been centuries ago: a long, winding ride through pale, undulating fields, leading to a dignified hilltop retreat. The three-story ivy-wrapped building is ringed by 20-foot obelisk-like cypress trees — a private citadel entered through a wrought-iron gate. Beyond the vista of olive groves, another fortresslike outcropping is visible in the distance: the mottled russet city of Siena, three miles away.
WHEN RENÉ CAOVILLA, the 82-year-old Venetian shoe designer, was first shown the Tuscan villa he bought in 1977, he fell in love with it instantly. He wasn’t only taken with the house, a 15th-century red brick monastery that had undergone a slow transformation into an austere 20-bedroom private home in the 17th century, but the Chianti landscape as well — the whole of classical history evoked in a flash.
If you’re enrolled only in original Medicare with a Medigap supplemental plan, and don’t use a drug plan, there’s no need to re-evaluate your coverage, experts say. But Part D drug plans should be reviewed annually. The same applies to Advantage plans, which often wrap in prescription coverage and can make changes to their rosters of in-network health care providers.
“The amount of information that consumers need to grasp is dizzying, and it turns them off from doing a search,” Mr. Riccardi said. “They feel paralyzed about making a choice, and some just don’t think there is a more affordable plan out there for them.”
Is there another way?
When creation of the prescription drug benefit was being debated, progressive Medicare advocates fought to expand the existing program to include drug coverage, funded by a standard premium, similar to the structure of Part B. The standard Part B premium this year is $144.60; the only exceptions to that are high-income enrollees, who pay special income-related surcharges, and very low-income enrollees, who are eligible for special subsidies to help them meet Medicare costs.
“Given the enormous Medicare population that could be negotiated for, I think most drugs could be offered through a standard Medicare plan,” said Judith A. Stein, executive director of the Center for Medicare Advocacy.
“Instead, we have this very fragmented system that assumes very savvy, active consumers will somehow shop among dozens of plan options to see what drugs are available and at what cost with all the myriad co-pays and cost-sharing options,” she added.
Advocates like Ms. Stein also urged controlling program costs by allowing Medicare to negotiate drug prices with pharmaceutical companies — something the legislation that created Part D forbids.